| Literature DB >> 32068975 |
Minoru Kouzuki1, Toshiaki Kato2, Kenji Wada-Isoe3,4, Shinya Takeda5, Atsuhito Tamura6, Yuichi Takanashi7,8, Shintaro Azumi9,10, Yoshinori Kojima11, Chikako Maruyama12, Maki Hayashi12, Michimi Itou13, Katsuya Urakami1.
Abstract
OBJECTIVE: We examined the benefits of a community-based program combining physical exercise, cognitive training, and education on dementia and lifestyle habits.Entities:
Mesh:
Year: 2020 PMID: 32068975 PMCID: PMC7085994 DOI: 10.1002/acn3.50993
Source DB: PubMed Journal: Ann Clin Transl Neurol ISSN: 2328-9503 Impact factor: 4.511
Figure 1Schedule of this study.
Figure 2Flow chart of the subjects of this study.
Baseline characteristics of subjects.
| Characteristics | All subjects | INT‐OBS group | OBS‐INT group |
|---|---|---|---|
| ( | ( | ( | |
| Age, mean ± SD | 77.3 ± 6.3 | 77.6 ± 6.8 | 77.0 ± 5.6 |
| Sex (male), | 47 (34.6%) | 24 (34.3%) | 23 (34.8%) |
| Medical history, | |||
| Dementia | 6 (4.4%) | 3 (4.3%) | 3 (4.5%) |
| Hypertension | 72 (52.9%) | 35 (50.0%) | 37 (56.1%) |
| Dyslipidemia | 17 (12.5%) | 10 (14.3%) | 7 (10.6%) |
| Diabetes mellitus | 30 (22.1%) | 15 (21.4%) | 15 (22.7%) |
| Cognitive function, mean ± SD | |||
| TDAS score | 7.0 ± 5.7 | 7.2 ± 5.9 | 6.8 ± 5.5 |
| Physical function, mean ± SD | |||
| Grip strength (kg) | 24.8 ± 6.6 | 23.8 ± 6.0 | 26.0 ± 6.9 |
| Sit‐to‐stand test ( | 16.6 ± 5.3 | 16.6 ± 5.4 | 16.7 ± 5.3 |
| One‐leg standing (sec) | 23.4 ± 23.2 | 23.8 ± 24.3 | 23.1 ± 22.0 |
| Anteflexion on sitting (cm) | 31.7 ± 8.2 | 30.9 ± 8.6 | 32.5 ± 7.7 |
| Ultrasonography, mean ± SD | |||
| Plaque scores (mm) | 2.7 ± 2.5 | 2.5 ± 2.5 | 2.9 ± 2.4 |
| Blood tests, mean ± SD | |||
| Total cholesterol (mg/dL) | 193.0 ± 32.4 | 195.2 ± 34.8 | 190.7 ± 29.6 |
| HDL cholesterol (mg/dL) | 58.9 ± 13.0 | 59.1 ± 13.3 | 58.8 ± 12.6 |
| LDL cholesterol (mg/dL) | 108.4 ± 26.3 | 111.2 ± 26.1 | 105.4 ± 26.2 |
| Glucose (mg/dL) | 122.8 ± 45.3 | 124.1 ± 51.8 | 121.4 ± 37.0 |
| HbA1c (%) | 5.8 ± 0.7 | 5.8 ± 0.8 | 5.7 ± 0.5 |
| Total protein (g/dL) | 7.1 ± 0.4 | 7.2 ± 0.4 | 7.1 ± 0.4 |
| Albumin (g/dL) | 4.3 ± 0.3 | 4.3 ± 0.3 | 4.3 ± 0.3 |
| MRI, mean ± SD | |||
| Number, | 105 | 52 | 53 |
| VARAD ( | 1.4 ± 0.8 | 1.5 ± 0.8 | 1.4 ± 0.8 |
INT, intervention; OBS, observation; TDAS, Touch Panel‐type Dementia Assessment Scale; VSRAD, voxel‐based specific regional analysis system for Alzheimer’s disease.
Results of cognitive test, physical examination, ultrasonography test, and MRI test.
| INT‐OBS group | OBS‐INT group | INT‐OBS vs. OBS‐INT group ( | ||||
|---|---|---|---|---|---|---|
| Mean ± SD |
| Mean ± SD |
| INT period | OBS period | |
| TDAS | ||||||
| Baseline test | 7.2 ± 5.9 | 0.434 | 6.8 ± 5.5 | 0.034 | 0.431 | 0.187 |
| Second test | 6.8 ± 5.9 | 7.3 ± 7.1 | ||||
| Third test | 7.7 ± 7.0 | 4.9 ± 4.3 | ||||
| Grip strength (kg) | ||||||
| Baseline test | 23.8 ± 6.0 | <0.001 | 26.0 ± 6.9 | <0.001 | <0.001 | <0.001 |
| Second test | 24.0 ± 6.5 | 25.2 ± 7.0 | ||||
| Third test | 26.0 ± 6.3 | 26.5 ± 7.7 | ||||
| Sit‐to‐stand test ( | ||||||
| Baseline test | 16.6 ± 5.4 | <0.001 | 16.7 ± 5.3 | <0.001 | 0.011 | 0.012 |
| Second test | 17.8 ± 6.0 | 17.2 ± 5.0 | ||||
| Third test | 19.8 ± 6.5 | 20.1 ± 5.4 | ||||
| One‐leg standing time (sec) | ||||||
| Baseline test | 23.8 ± 24.3 | <0.001 | 23.1 ± 22.0 | <0.001 | 0.197 | 0.064 |
| Second test | 31.9 ± 22.9 | 32.4 ± 23.7 | ||||
| Third test | 36.6 ± 21.7 | 39.5 ± 21.3 | ||||
| Anteflexion on sitting (cm) | ||||||
| Baseline test | 30.9 ± 8.6 | <0.001 | 32.5 ± 7.7 | <0.001 | 0.342 | 0.003 |
| Second test | 32.2 ± 6.7 | 31.9 ± 7.9 | ||||
| Third test | 34.3 ± 7.4 | 35.0 ± 7.7 | ||||
| Plaque scores (mm) | ||||||
| Baseline test | 2.5 ± 2.5 | 2.9 ± 2.4 | ||||
| Second test | 2.9 ± 2.6 | 0.231 | 3.4 ± 2.7 | 0.189 | 0.049 | 0.051 |
| Third test | 2.6 ± 2.3 | 2.8 ± 2.2 | ||||
| VSRAD (z‐score) | ||||||
| Baseline test | 1.46 ± 0.79 | 0.361 | 1.42 ± 0.83 | 0.871 | – | |
| Second test | – | – | ||||
| Third test | 1.35 ± 0.55 | 1.40 ± 0.83 | ||||
INT, intervention; OBS, observation; TDAS, Touch Panel‐type Dementia Assessment Scale; VSRAD, voxel‐based specific regional analysis system for Alzheimer’s disease.
Significant difference between Baseline and Second test by post hoc test (P < 0.05).
Significant difference between Baseline and Third test by post hoc test (P < 0.05).
Significant difference between Second and Third test by post hoc test (P < 0.05).
Sample sizes for tests other than VSRAD analysis are n = 70 (Baseline test), n = 63 (Second test), and n = 60 (Third test). For VSRAD analysis, sample sizes are n = 52 (Baseline test) and n = 41 (Third test).
Sample sizes for test other than VSRAD analysis are n = 66 (Baseline test), n = 65 (Second test), and n = 54 (Third test). For VSRAD analysis, sample sizes are n = 53 (Baseline test) and n = 43 (Third test).
Figure 3Mean changes from pre‐intervention to post‐intervention or pre‐observation to post‐observation in the TDAS score (A), physical examination performances (B–E), and plaque status by carotid ultrasonography (F). All data are expressed as mean ± standard error, and the number on the error bar is the mean value. Sample sizes are n = 65 (CTL1), n = 125 (CTL2), and n = 117 (INT). *P < 0.05, **P < 0.01. TDAS, Touch Panel‐type Dementia Assessment Scale; CTL1, mean change from pre‐observation to post‐observation in observation‐first group only (Control 1); CTL2, mean change from pre‐observation to post‐observation in all subjects (Control 2); INT, mean change from pre‐intervention to post‐intervention in all subjects (Intervention).